Biotech Daily

Tuesday June 10, 2025

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: OPTISCAN UP 13%; AMPLIA DOWN 11%**

*** VICTORIA'S DANNY PEARSON 'THE MINISTER ON A MISSION'**

*** GOODBYE GENETIC TECHNOLOGIES**

*** WEHI BLOOD TEST DETECTS COELIAC DISEASE, WITHOUT GLUTEN**

*** AKAAL PHASE II TRIAL SHOWS TAKP-119 REDUCES ECZEMA, ITCHING**

*** DOHERTY: 'COVID-19 mRNA VACCINE MAY CURE HIV'**

*** AVITA RECELL 'REDUCES HOSPITALIZATION 36%'**

*** IMRICOR WINS NORTHSTAR EUROPEAN CE MARK**

*** SYNTARA SNT-5505 US FDA FAST TRACK STATUS FOR MYELOFIBROSIS**

*** OPTISCAN DEVELOPS INSPECTA VETERINARY MICROSCOPE**

*** BOTANIX TAKES $48m KREOS CAPITAL LOAN**

*** CHIMERIC TAKES $2.5m ENDPOINTS RDTI LOAN**

*** ARGENICA: FDA 'CLINICAL HOLD' ON ARG-007 FOR STROKE IND**

*** OPYL STRATEGIC, BOARD REVIEW; APPOINTS ADVISOR**

*** ANTEOTECH REDUCES STAFF, CUTS COSTS**

*** DORSAVI REQUESTS 'LICENCE, CAPITAL RAISING' TRADING HALT**

*** ISLAND REQUESTS 'TRIAL RESULTS' TRADING HALT**

*** DR MATUA CHARLIE JANSEN REDUCES TO 5.45% OF VITURA**

*** CSL APPOINTS CAMERON PRICE DIRECTOR**

*** GREG MOSS, DAVID ROBERTS REPLACE ANTERIS DIRECTOR DR WENYI GU**

MARKET REPORT

The Australian stock market was up 0.84 percent on Tuesday June 10, 2025, with the ASX200 up 71.5 points to 8,587.2 points. Twenty-two of the Biotech Daily Top 40 companies were up, 12 fell and six traded unchanged. All four Big Caps were up.

Optiscan was the best, up 1.5 cents or 13.0 percent to 13 cents, with 60,089 shares traded. Prescient climbed 12 percent; Resonance rose 7.5 percent; Atomo, Clarity and Mesoblast were up more than six percent; Actinogen, Avita and Nova Eye improved more than four percent; Aroa and Botanix were up three percent or more; Cynata, Polynovo and Pro Medicus rose more than two percent; Clinuvel, Cyclopharm, Immutep, Nanosonics, Neuren, Resmed and Telix were up more than one percent; with Cochlear, CSL, Dimerix, EBR and Emvision up by less than one percent.

Amplia led the falls, down 0.7 cents or 10.6 percent to 5.9 cents, with 3.1 million shares traded. Proteomics lost 7.1 percent; Compumedics, Curvebeam and Impedimed were down more than five percent; Genetic Signatures and Medical Developments fell four percent or more; Micro-X was down 3.9 percent; Alcidion and Starpharma shed more than two percent; with Orthocell and SDI down by more than one percent.

VICTORIA GOVERNMENT

By Deputy Editor Jamie Miller

Victoria's Minister for Economic Growth, Jobs and Finance Danny Pearson says a review of Government investment in start-ups and innovation will be held this year.

Speaking to Biotech Daily, at his Moonee Ponds offices, on a cool, grey-skied Friday morning, the 52-year-old Minister said he planned to "get moving quickly" on a review of what he says is a "congested" system of Government investment in start-ups and innovation, including biotechnology.

Mr Pearson said he wanted to make sure the Government was operating "as efficiently and as effectively as we can" and he intended to conduct a review of the interface between Breakthrough Victoria, Launch Vic and the Federal Government's National Reconstruction Fund "over the coming months".

Born and raised in Wantirna in Melbourne's Eastern suburbs, Mr Pearson said politics was not always the plan, but found himself working as a researcher for then opposition leader John Brumby, after graduating from the University of Melbourne with a Bachelor of Arts.

Mr Pearson said he also earned a Master of Business Administration from the University of Melbourne and worked for 15 years at the government relations and public affairs firm Hawker Britton prior to his election to the seat of Essendon in 2014.

"I'm not a career politician, it hasn't been my whole life," Mr Pearson noted.

Mr Pearson said he had been charged with between 12 and 15 portfolios in just under five years. "I don't have a lot of time; I always get moved on to the next thing … so I've just got to move as quickly as I can to get as much done as I can".

Mr Pearson said he felt "a degree of hope, optimism and confidence" in the Government's investment in medical research and biotechnology.

For Mr Pearson, this starts with reviewing the Government investment.

The Victoria Government's start-up investment fund Launch Vic was established in 2016 and Breakthrough Victoria had been around for about five years, he said.

After six months as Minister for Economic Growth, Jobs and Finance, Mr Pearson said he wanted to understand the performance of the two funds and the way they were managed alongside the Federal Government's $15 billion National Reconstruction Fund "to improve performance and better support the sector".

"I've looked at Breakthrough Victoria … [and] Launch Vic" Mr Pearson said, and "having them both in a marketplace where they may be tripping over each other, it might not be as efficient as it could be".

Mr Pearson said the value of Victoria's start-up sector had increased from about $5 billion in 2016 to about $130 billion today.

Investment firms specializing in biotechnology and medical devices managed more than $3.4 billion in venture capital funds in Victoria, Mr Pearson said, with the sector contributing $5.4 billion to the State, an 18 percent increase over the last five years.

“Last year, Victoria exported $3.8 billion of health technology products, a boost of 91 percent since 2015,” Mr Pearson added.

The Minister said that the Victorian Government had invested $1 billion over 10 years in the sector, with a four-to-one return on investment.

Mr Pearson said alongside the review, he would advocate for the removal of impediments, if there were any, to what superannuation funds could and could not invest.

“We are home to the superfunds, which is great, but how can we find ways of incentivizing the super funds to invest more in [the start-up] space?” Mr Pearson asked. “How can we try and make this more attractive and more appealing to the industry super funds, particularly in the context of the turmoil that’s being unleashed in the global markets?”

Mr Pearson suggested that finding ways to free up capital and allow the super funds to “at least contemplate or consider … riskier investments”, including in start-ups and companies in the research and development phase, may be the answer.

“We have been terrible as a nation when it comes to commercializing university research, and I really want to try and get a sense of what we can be doing better,” Mr Pearson said.

Budgeting for success

Mr Pearson said the 2025 State Budget included a $150 million Victoria Investment Fund which was designed “to attract footloose capital”, with $50 million for regional support and a $100 million fund to provide “the fiscal firepower” to bid for companies to invest in Victoria rather than other States.

“We have structured this budget in such a way as to play to our competitive strengths, certainly from my perspective I want to find ways to ensure the [biotechnology and medical technology] sector goes from strength to strength,” Mr Pearson said.

Mr Pearson said the State Budget provided $24 million in funding to the Operational Infrastructure Support (OIS) program for medical research institutions, which would help fund the “non-research elements” of research expenses, such as conference costs.

The State Budget included $3 million, Mr Pearson added, of matched funding to medical research institutes to attract 10 individuals or researcher teams from outside of Australia to relocate and conduct their research in Victoria.

Mr Pearson said Victoria had a strong social safety net, valued academic freedom, freedom of thought and “a plurality of views”, particularly for academic institutions, a nod to the conflict between US President Donald Trump’s administration and Boston’s Harvard University.

Separation of powers

“As an elected official for the seat of Essendon, and as Minister with responsibility for medical research, it is not my job to be reaching into academic institutions and telling academics what they should and shouldn’t be doing, studying and publishing”.

“We want to be really clear … to the medical researchers of the world, but particularly to those in America, that if you're doing really interesting stuff and you value your freedoms, and you want to live in a tolerant, pluralistic society … we would love you here,” Mr Pearson said.

Mr Pearson reiterated the words of Prime Minister Anthony Albanese when he stated there was “an opportunity for Australia to be the ‘adults in the room’”.

“[Victoria is] so fortunate with the strength and calibre” of its medical research sector, Mr Pearson said, which he said was birthed by former Victoria Premiers Steve Bracks and John Brumby’s vision of Melbourne’s Parkville precinct as “a future centre for innovation and research” almost 25 years ago.

Boston, London and Melbourne

“Victoria is the medical research centre of Australia and is among the world’s best, and our investment has positioned us alongside places like Boston and London,” Mr Pearson said.

“We are one of the world’s leading health technology hubs, supported by nine universities and 18 globally renowned research institutes, and also the biotech capital of the Southern Hemisphere,” the Minister said.

Mr Pearson added that the State was “one of only three cities with two universities amongst the top 40 university rankings for life sciences and medicine”, according to the Quacquarelli Symonds (QS) world university rankings.

“The biggest challenge we’ve got is just the lack of certainty,” Mr Pearson said.

“When you have got this level of uncertainty and turmoil, you kind of have to do the opposite, ignore the white noise, be clear, focused, calm and deliberate”.

Mr Pearson said he was aware that there was no second place in medicine, “the patient will only go for the best-in-class”.

The Minister said that beyond monetary investment, the State Government would “work with the sector more broadly and build partnerships” to continue to improve Victorian medical technology and biotechnology.

“All we have is our word,” Mr Pearson concluded.

GENETIC TECHNOLOGIES

Genetic Technologies says that after 25 years as a biotechnology company, it will become a “wealth advisory business” pending shareholder and regulatory approval.

Genetic Technologies said it had acquired the financial planning businesses Ellerfield Wealth and Walker Capital Private Wealth, for $7,840,000 in scrip, which were 51 percent-owned and 100 percent-owned, respectively, by its chair Michael Walker.

The company said it intended to undergo a consolidation, at an as yet unknown rate.

Genetic Technologies said the purchase was “a significant milestone for the company to transition into a diversified financial services group” … [and was] a change in the nature and a scale of [its] activities [and] accordingly, shareholder approval will be required” to re-comply with the requirements of Chapters 1 and 2 of ASX Listing Rules.

Genetic Technologies history

In 2000, mining company Duketon Goldfields Ltd acquired the Dr Mervyn Jacobson-chaired, Switzerland-based Genetype, which had “made significant discoveries over the last 10 years in the field of advanced DNA genetics”, for two thirds of its issued capital, and changed its name to Genetic Technologies.

In its 2008 preliminary final report, the company said its $10.8 million revenue was from licencing its “family of ‘non-coding’ analysis and mapping patents” as well as fee-for-service genetic testing including medical diagnostics and animal pedigrees.

Genetic Technologies founder and 41.65 percent shareholder Dr Jacobson spilled the company’s board, including chair Henry Bosch, a former corporate regulator, managing director Michael Ohanessian, former Federal Treasurer John Dawkins, David Carruthers and Monash University deputy chancellor Dr Leanne Rowe (BD: Sep 18, Nov 19, 2008).

Biotech Daily reported that the company’s shares had traded above $1.00, with a market capitalization of more than $100 million, until March 2007 both fell about 50 percent.

Four years later, the company voted to remove chair Dr Mel Bridges and director Huw Jones from the board; Dr Bridges said it was regrettable that a company with potential was unable to reach middle ground with its major shareholder (BD: Nov 27, 2012).

Biotech Daily believed the votes primarily came from founder and former chief executive officer Dr Jacobson and associates.

In 2014, Dr Jacobson was found guilty on two charges of conspiracy and 33 charges of market manipulation in the Supreme Court of Victoria; and was sentenced to two years and eight months’ gaol, with a minimum of 12 months (BD: Nov 5, 28, 2014).

The same year, Genetic Technologies sold its Australian Genetics business, including canine, medical and paternity testing to Primary Health Care subsidiary Specialist Diagnostics Services for $2 million in cash to focus on US commercialization of its diagnostics including breast cancer risk test Bregavenplus (BD: Nov 19, 2014).

In 2021, Genetic Technologies said it acquired the Fort Lauderdale, Florida-based Belhealth Investment Fund’s Easy DNA for $US4 million ($A5.5 million) in cash and scrip (BD: Aug 16, 2021).

Last year, the company went into voluntary administration; and later, sold its Genetype cancer and disease risk assessment test business for $625,000 to Rhythm Biosciences and its Easy DNA and Affinity DNA direct-to-consumer businesses for $525,000 to Endeavour DNA Inc (BD: Nov 20, Dec 16, 2024; Jan 19, 20, Feb 5, 2025).

Last month, the administrators said a shareholder meeting overwhelmingly approved a deed of company arrangement from Sydney’s Benelong Capital for Walker Capital to acquire 88 percent of the company and its board resigned (BD: May 14, 2025).

Genetic Technologies was in a suspension and last traded at 3.9 cents.

THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says a 181-volunteer study shows its blood test for gluten-specific T-cells detects coeliac disease “even when no gluten has been eaten”.

WEHI said following a 2021 pilot study its researchers had tested an “‘in-tube’ gluten challenge blood test” on samples from 181 volunteers at the Royal Melbourne Hospital, including 75 people with treated coeliac disease, 13 with active, untreated coeliac disease, 32 people with non-coeliac gluten sensitivity and 61 health controls.

The Institute said participant blood samples were then mixed with gluten in a test tube for a day to see if the immune marker interleukin 2 (IL-2) signal appeared.

WEHI said that the study showed the test could detect coeliac disease with “up-to 90 percent sensitivity and 97 percent specificity, even in patients following a strict gluten free diet”.

The Institute said its study confirmed previous results that the IL-2 signal only increased in the volunteers with coeliac disease, showing the immune response to gluten can be detected in a tube, without a gluten challenge.

WEHI said the blood test was developed with Brisbane’s Novoviah Pharmaceuticals.

The Institute said a reliable diagnosis was possible only when gluten was consumed regularly, with gastroscopy and biopsy usually required to identify intestinal injury.

WEHI said its “new test could boost rates of diagnosis, identify patients at risk of severe reactions to gluten and detect silent coeliac disease in people who are asymptomatic”.

The study, titled ‘Blood-based T Cell Diagnosis of Celiac Disease’ was published in the journal Gastroenterology and available at: https://bit.ly/4n90zqa.

WEHI researcher Prof Jason Tye-Din said every approved method to diagnose coeliac disease required people to eat gluten.

“There are likely millions of people around the world living with undiagnosed coeliac disease simply because the path to diagnosis is difficult, and at times, debilitating,” Prof Tye-Din said.

“This new test promises to simplify and speed up accurate diagnosis, while also avoiding the suffering that comes with eating gluten for extended periods to reactivate coeliac disease,” Prof Tye-Din said.

“By eliminating the need for a gluten challenge, we’re addressing one of the biggest deterrents in current diagnostic practices,” Prof Tye-Din said.

“This test could be a game-changer, sparing thousands of people the emotional and physical toll of returning to gluten. It's a major step towards faster, safer diagnosis,” Prof Tye-Din said.

WEHI researcher Olivia Moscatelli said the test was “a promising new tool to support diagnosis, especially for people who can’t be diagnosed with the currently available methods”.

“We also found the strength of the IL-2 signal correlated with the severity of a patient’s symptoms, allowing us to predict how severely a person with coeliac disease might react to gluten, without them actually having to eat it,” Ms Moscatelli said.

“The test’s performance in individuals with other autoimmune conditions in addition to coeliac disease, such as type 1 diabetes or Hashimoto’s thyroiditis, is also unmatched,” Ms Moscatelli said.

“Some diagnostic tests give false positives in the presence of other autoimmune diseases, but this was not an issue for this test,” Ms Moscatelli said.

“This is largely because the technology we use is highly sensitive and can detect the IL-2 signal at exceptionally low levels,” Ms Moscatelli said.

“It’s like the equivalent of being able to detect a single grain of sand in a swimming pool,” Ms Moscatelli said.

AKAAL PHARMA PTY LTD

Melbourne's Akaal Pharma says a 139-patient, phase II trial shows its Takp-119 for atopic dermatitis led to "statistically significant reductions in inflammation and pruritus".
Akaal said its Takp-119 topical treatment, a selective sphingosine 1-phosphate-receptor subtype-1 (S1P1) agonist, led to a 63.3 percent reduction in lesion eczema severity index score ($p < 0.0001$), compared to 21.5 percent in the placebo group.
The company said Takp-119 led to a "significant reduction of 72.7 percent in visual analogue scale for pruritus", or itchiness, compared to 1.45 percent in the placebo group.
Akaal said the study was conducted at five sites in India, with treatment leading to 97 patients, or 69.7 percent, having mild or no itchiness compared to 2.9 percent for placebo.
The company said Takp-119 met both its primary and secondary endpoints and significantly reduced disease severity and itch in patients with atopic dermatitis.
Akaal said Takp-119 was well tolerated with no side effects typically observed in other therapies and its favorable safety profile, particularly the absence of bradycardia and minimal immune suppression made it a "uniquely differentiated candidate in [its] class".
The company said "Takp-119 could address a critical unmet need for a safe, effective and non-steroidal treatment option for atopic dermatitis and related pruritus".
Akaal chief executive officer Dr Tony Rajic said the study was "a significant milestone for Akaal Pharma as we continue to actively prioritize and expand our development programs to bring new and effective treatments into the market".
Akaal Pharma is a private company.

PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY

The Doherty Institute says it has found that the messenger RNA used in Covid-19 vaccines may be "a potential strategy to find a cure" for HIV.
The Doherty Institute said HIV had the unique ability to hide in a type of white blood cell called resting CD4+ T-cells "ready to re-emerge if treatment is stopped".
The Institute said this "HIV 'reservoir' has long been one of the greatest challenges in the search for a cure".
The Doherty Institute said a laboratory study using the same technology behind mRNA Covid-19 vaccines had "discovered a new way to deliver mRNA to the elusive HIV reservoir and coax HIV out of hiding".
The Institute said researchers packaged mRNA inside lipid nano-particles, or fat-like bubbles "and transported it into HIV-infected cells, where it prompted the cells to expose the dormant virus".
The study, titled 'Efficient mRNA delivery to resting T cells to reverse HIV latency' was published in Nature at: https://www.nature.com/articles/s41467-025-60001-2.
The Doherty Institute said the study was an important proof-of-concept that it hoped "could be a turning point in the field".
University of Melbourne researcher and co-author Dr Paula Cevaal said the researchers "programmed mRNA to tell infected cells to 'give up' the virus and make it visible".
"But getting the mRNA into those cells was the challenge," Dr Cevaal said.
"We were excited to see that a new lipid nanoparticle, essentially a tiny fat bubble, could carry mRNA into HIV-infected cells successfully," Dr Cevaal said.
"It forced the virus out of hiding, which is exactly what we need to start clearing it from the body," Dr Cevaal said.
"This is the first time this strategy has been shown to work in HIV-infected cells," Dr Cevaal said. "Our hope is that this new nanoparticle design could be a new pathway to an HIV cure."

AVITA MEDICAL

Avita says a 6,300-patient, retrospective study shows Recell spray-on-skin reduces patients' length of hospital stay by 6.2 days (35.7%) compared to standard skin grafts.
Avita said the study analyzed registry data from patients treated with Recell between 2019 and 2024 and found that in patients with burns covering less than 30 percent of total body surface area Recell alone reduced average patient hospital stay by 6.2 days, compared to split-thickness autografts.
The company said the study showed that the use of Recell led to about $300 million in cost savings in the five-year study period, due to reduced patient length of stay.
Avita said the results, titled 'The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective' were presented at the British Burn Association meeting in Brighton, England from June 4 to 6, 2025.
Avita chief executive officer Jim Corbett said reducing hospital length of stay had "a direct impact on the cost of care, especially in complex cases like severe burns".
"This analysis further supports previously published data, reaffirming Recell's proven clinical and economic value by reducing hospital stays and accelerating patient recovery," Mr Corbett said.
Avita was up 8.5 cents or 4.7 percent to $1.89.

IMRICOR MEDICAL SYSTEMS

Imricor says it has Conformité Européene (CE) mark approval for its Northstar system for use with interventional cardiac magnetic resonance imaging (ICMR).
Imricor said the certification, under the European Union's Medical Device Regulation, approved its device as a class IIa medical device, and that Northstar included a computer workstation and a software application.
The company said the approval allowed the commercial launch of its product in Europe and the Middle East.
Imricor managing-director Steve Wedan said CE mark approval for Northstar was "a transformative step towards establishing a global platform for MRI-guided interventions".
"I often say that Northstar's purpose is to transform [magnetic resonance] imaging from something analogous to taking a picture with a still camera into something analogous to shooting a live video," Mr Wedan said. "When you're guiding a medical procedure with MRI, you need 'live video' capabilities."
"This is more than just a regulatory win," Mr Wedan said. "It's the launch of our software era, and as we grow and expand interventional MRI applications even beyond cardiac ablations, I envision Northstar growing and expanding to become the central hub of every interventional MRI practice."
Imricor was up four cents or 2.4 percent to $1.70.

SYNTARA

Syntara says its SNT-5505 has US Food and Drug Administration fast track status for myelofibrosis patients with an inadequate response to JAK-inhibitor therapy.
Syntara said it continued its phase II trial of SNT-5505, with additional interim data expected to be presented on June 15, 2025.
Syntara managing-director Gary Phillips said fast track designation was "an outstanding development for Syntara".
Syntara was unchanged at 6.9 cents with 4.8 million shares traded.

OPTISCAN IMAGING

Optiscan says it has developed Inspecta, a microscopic imaging device designed specifically for use on animals in veterinary medicine.

Last year, Optiscan said it had a five-year research agreement with the University of Minnesota College of Veterinary Medicine to research its endo-microscope for cancer detection in animals (BD: Aug 19, Nov 18, 2024).

Today, the company said the "compact, durable and portable device [was] …ruggedized, allowing use across multiple settings from an in-office environment to fieldwork in rural surroundings".

Optiscan said the microscope offered "real-time, non-invasive imaging for a broad range of animals that is far superior to the way medical conditions are currently diagnosed and treated by veterinary medicine".

The company said the device would be tested at the University of Minnesota College of Veterinary Medicine, allowing it to gather data on the clinical utility of the microscope and support regulatory submissions.

Optiscan said the initial focus would be showing the ability of Inspecta to improve diagnostics and treatment for companion animals and it expected the device would also "offer immense potential across all categories of veterinary medicine".

Optiscan managing-director Prof Camile Farah said Inspecta was "based on the company's life sciences imaging platform, Viewnvivo, and offers veterinarians an easy to use, portable and robust imaging device which is purposefully designed for their particular needs".

"It can be used for both in-vivo and ex-vivo applications, broadening the appeal and applicability of the technology to the widest possible audience in veterinary medicine," Prof Farah said.

Optiscan was up 1.5 cents or 13.0 percent to 13 cents.

BOTANIX PHARMACEUTICALS

Botanix says it has taken a $US30 million ($A48 million) loan from London's Kreos Capital at 9.95 percent annual interest, secured against its assets.

Botanix said the loan included a $US20 million first tranche, expected to be drawn down today, and a second tranche of $US10 million available up-to October 1, 2026.

The company said the lender could convert up-to 20 percent of the principal loan amount drawn down into shares at a conversion price of the Euro equivalent of 130 percent of 33 Australian cents.

Botanix said each tranche had an initial interest-only repayment period, followed by 30 monthly payments of principal and interest, and were repayable by October 1, 2028 and July 1, 2029, respectively.

The company said it would issue Kreos Capital 3,030,303 warrants on the draw-down of the first tranche and 1,515,151 warrants on the draw-down of the second tranche, exercisable at 33 cents each within five years from the issue date.

Botanix said the loan would "support its growth and strategic initiatives and follows the recent successful $40 million capital raising conducted by the company to accelerate the commercial launch of Sofdra, sofpironium topical gel, 12.45 percent".

Botanix chair Vince Ippolito said the "flexibility provided by the facility will allow us to make rapid decisions to support the acceleration of Sofdra sales and move quickly to expand the platform as opportunities present themselves over the coming year".

Botanix was up one cent or three percent to 34 cents with 12.7 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says it has taken a $2,500,000 loan from Sydney's Endpoints Capital against its expected Federal Government Research and Development Tax Incentive.
Chimeric said the loan included interest "charged at [an undisclosed] commercial rate" and was repayable by December 31, 2025, following receipt of its Research and Development Tax Incentive from the Australian Taxation Office for the year to June 30, 2025.
The company said the funds would be used for its clinical trials and working capital.
Chimeric was unchanged at 0.5 cents with 5.4 million shares traded.

ARGENICA THERAPEUTICS

Argenica says its US Food and Drug Administration investigational new drug application of ARG-007 for acute ischaemic stroke has been put on "clinical hold".
In an investor presentation to the ASX on May 19, 2025, Argenica said it had submitted an investigational new drug application for ARG-007 to the FDA, as well as a fast-track application and that the status would provide more frequent communication with the FDA and eligibility for accelerated approval, priority review and rolling review.
Today, the company said the FDA had "indicated that the non-clinical data package provided in the application was "not adequate to support initiation of a proposed acute ischaemic stroke trial in the US at this time".
Argenica said "no further details on the FDA's additional requirements have been provided at this time, however the company expects further detailed correspondence form the FDA within 30 days".
The company said the FDA response did not impact its phase II trial in Australia, with data expected by October 2025.
Argenica said it had expected "there may be some challenges in receiving an open [investigational new drug] within the 30-day time period due to current resourcing challenges at the FDA, hence the decision to submit the … application much earlier than required to actually start anticipated future clinical trials in the US".
The company said it "had addressed all requests by the FDA for non-clinical information outlined in its pre-[investigational new drug] type B meeting … [and was] committed to providing any additional specific data that the FDA may require".
Argenica managing-director Dr Liz Dallimore said that although the company was "obviously disappointed with the hold placed on our [acute ischaemic stroke investigational new drug] application, we are confident we can provide the additional data required by the FDA in a timely manner".
Argenica fell three cents or 3.8 percent to 75.5 cents.

OPYL

Opyl says it has conducted a strategic review, will assess the composition of its board and management and has appointed Sandton Capital Advisory as an advisor.
Opyl said the review was designed to position the company as "a vertically integrated leader in [artificial intelligence] drug development and clinical trial process, ensuring robust platform capabilities and sustained long-term growth".
The company said it would focus on technology development, collaboration and acquisition, identifying complementary applications beyond biotechnology trials, securing commercial agreements, using its data and hiring board and management.
Opyl said it had appointed Sandton Capital Advisory to advise its review outcomes.
Opyl fell 0.1 cents or 4.55 percent to 2.1 cents.

ANTEOTECH

Anteotech says it has made eight redundancies in personnel to cut costs following a strategic review to streamline operations and reduce “new product development”.
Anteotech said it had developed, tested and validated multiple products currently being commercialized across the lithium-ion battery and life sciences markets and in the past six weeks had undertaken a strategic review on accelerating commercialization.
The company said the redundancies included chief operating officer Katrina Byrne and that prior to the redundances chief marketing officer Tsui Lian had resigned.
Anteotech said its organization restructure was informed by the analysis of the skills and experience needed to deliver its revised strategy whilst maintain workforce flexibility, and that cross-training of staff in the coming months would support resource sharing and enable the business to respond to customer requirements.
The company said it would hire five additional employees to support the strategy, including four in sales and marketing, with one based in Brisbane and three based in India.
Anteotech said it would not appoint an additional director or recruit a permanent full-time chief executive officer or managing-director “to preserve shareholder capital” and would retain its three directors, as required under its constitution.
The company said the personnel changes would lead to expected reduced annual operating expenses of about $1.6 million.
Anteotech said that with commercialization of existing products prioritized and product development expected to be advanced through strategic partnerships, spending on raw materials for research and development would reduce.
Anteotech was up 0.1 cents or 14.3 percent to 0.8 cents with 13.5 million shares traded.

DORSAVI

Dorsavi has requested a trading halt “pending an announcement by the company to the market in relation to execution of a … licence agreement and capital raising”.
Trading will resume on June 12, 2025, or on an earlier announcement.
Dorsavi last traded at 1.6 cents.

ISLAND PHARMACEUTICALS

Island has requested a trading halt “pending an announcement … regarding the analysis of clinical results relating to its phase IIa/b … trial of ISLA-101”.
Trading will resume on June 12, 2025, or on an earlier announcement.
Island last traded at 20 cents.

VITURA HEALTH

Dr Matua Hasyo Charlie Jansen says he has reduced his substantial shareholding in Vitura from 42,704,345 shares (6.51%) to 36,079,345 shares (5.45%).
The Sydney-based Dr Jansen said that as trustee for Whanau Family Trust he sold 3,500,000 shares off-market on May 27, 2025 for $227,500, or 6.5 cents a share, and 3,125,000 shares off-market on June 6, 2025 for $200,000, or 6.4 cents a share.
Vitura fell 0.3 cents or 4.35 percent to 6.6 cents.

CSL

CSL says it has appointed Cameron Price as an independent, non-executive director, effective from October 1, 2025.

CSL said Mr Price was general counsel and chief risk officer at the Future Fund, Australia's sovereign wealth fund, where he managed investment of several funds including the $240 billion Future Fund and $24 billion Medical Research Future Fund.

The company said prior to his role at the Future Fund Mr Price had been a lawyer, partner and board member at law firm Allens, working in mergers and acquisitions, equity capital markets and corporate governance and compliance.

CSL said Mr Price held a Bachelor of Laws and Bachelor of Economics from Melbourne's Monash University.

CSL was up $2.21 or 0.9 percent to $244.13 with 771,721 shares traded.

ANTERIS TECHNOLOGIES GLOBAL CORP (FORMERLY ADMEDUS)

Anteris says Gregory Moss and David Roberts will replace Dr Wenyi Gu, who resigned on June 6, as directors, effective from June 8, 2025.

Anteris said Mr Moss was Evommune Inc chief business officer and corporate secretary, had been chief compliance officer and general counsel at Kadmon, a Sanofi company and was on the board of Vitls Inc.

The company said Mr Moss held a Bachelor of Arts and Bachelor of Laws from Sydney's Macquarie University.

Anteris said Mr Roberts was head of Lemaitre Vascular Inc, had been head of development for BUCA Inc and an associate of Harbourvest Partner and was currently a director of Lemaitre Vascular, Lexington Medical and Parasole Restaurant Holdings.

The company said Mr Roberts held a Bachelor of Arts from Providence, Rhode Island's Brown University and a Master of Business Administration from California's Stanford University.

In 2018, the then Admedus said that Star Bright Holding nominee had been appointed as a director (BD: Oct 4, 2018)

Anteris was up 68 cents or 9.7 percent to $7.68 with 170,286 shares traded.